Development and relapse of gastroduodenal ulcer in patients taking nonsteroid anti-inflammatory drugs: effects of standard risk factors


Cite item

Full Text

Abstract

Aim. To investigate incidence and recurrence rate of endoscopic ulcers in patients with rheumatic diseases (RD) taking NSAID in respect to factors of NSAID gastropathy risk. Material and methods. Endoscopic findings in the gastrointestinal tract were analysed for 6103 patients (age 50.1 ± 14.6 years, 83.1% females) with RD taking NSAID regularly, 1642 of them took also glucocorticoids (GC). Control RD patients (n = 504) matched by age and sex took no NSAID, GC and low dose aspirin a month and more before the trial. Results. Gastric or duodenal ulcers were detected in 763 (12.5%) RD patients treated with NSAID, in 20 (4.0%) in the control group, p < 0.0001. Ulcers were more frequent in older patients (65 years of age and older) with ulcer history treated with nonselective NSAID in combination with low aspirin doses (15.1 and 12.0, p < 0.05; 27.3 and 9.7%, p < 0.001; 13.1 and 9.8%, p<0.001; 19.1 and 12.2%, p < 0.001; respectively). No significant difference in ulcer occurrence was observed in patients given NSAID+GC and NSAID only (11.3 and 12.9%, respectively; p = 0.041). The recurrence rate was assessed in 407 patients with NSAID-induced ulcer 12 months later. Control consisted of 1640 patients having no ulcer, multiple erosions after 12 months of regular intake of NSAID. Ulcer recurrence rose in 163 of 407patients (40%) while only in 107 of 1640 controls (6.5%, p < 0.0001). Old age and GC administration had no impact on the recurrence rate. Recurrences were less frequent in patients taking nonselective NSAID than those taking nonselective ones (23.4 and 46.5%, respectively; p < 0.001) and in patients treated with NSAID in combination with proton pump inhibitors (24.6 and 42.6%, respectively; p < 0.001). Prophylactic intake of H-2 blockers did not reduce recurrence rate. Conclusion. Old age, ulcer history and intake of nonselective NSAID increased the risk of endoscopic GI ulcer. Combined use of NSAID and GC did not increase the risk of ulcer development or recurrence. In a year or later of NSAID continuation recurrences arose in 40% patients with NSAID-induced ulcers. Recurrence risk was reduced by selective NSAID and proton pump inhibitors.

About the authors

A E Karateev

ГУ Институт ревматологии РАМН, Москва, Россия

V A Nasonova

ГУ Институт ревматологии РАМН, Москва, Россия

References

  1. Применение нестероидньх противовоспалительных препаратов: Клинические рекомендации / Насонов Е. Л., Лазебник Л. Б., Мареев В. Ю. и др. М; 2006.
  2. Cryer В. СОХ-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: Is there approach sufficient for patients at highest risk of NSAID-induced ulcers? Gastroenterology 2004; 127: 1256-1262.
  3. Lain L. Nonsteroidal anti-inflammatory drag gastropathy. Gastrointest. Endosc. Clin. N. Am. 1996; 6: 489-504.
  4. Dubois R., Melmed G., Henning J., Lane L. Guidelines for the appropriate use of nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment. Pharmacol. Ther. 2004; 19: 197-208.
  5. Lanas A. Prevention and treatment of NSAID-induced gastrointestinal injury. Curr. Treat. Opt. Gastroenterol. 2006; 9: 147-156.
  6. Graham D., White R., Morelend L. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann. Inter. Med. 1993; 119: 257-262.
  7. Hawkey C., Svoboda P., Fiedorowicz-Fabrycy I. et al. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J. Rheumatol. 2004; 31: 804-1810.
  8. Каратеев A. E., Насонов E. Д. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России. Рус. мед. журн. 2006; 15: 1073-1078.
  9. Raskin J., White R., Jackson J. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparson of three regimens. Ann. Intern. Med. 1995; 123: 344-350.
  10. Ekstrom P., Carling L., Wetterhus S. et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand. J. Gastroenterol. 1996; 31: 753-758.
  11. Taha A. S., Hudon N., Hawkey C. J. et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1996; 334: 1435-1439.
  12. Lain L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessery? Rev. Gastroenterol. Dis. 2004; 4: 33-41.
  13. Hawkey C. Cyclooxygenase inhibition: between the devil and deep blue see. Gut 2002; 50: 1125-1130.
  14. Perez Gutthann S., Garcia Rodriguez L., Raiford D. Individual NSAIDs and other risk factor for upper gastrointestinal bleeding and perforation. Epidemiol. 1997; 8: 18-24.
  15. Garcia Rodriguez L. A., Cattarzzi C., Troncon M. G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other NSAIDs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med. 1998; 158: 33-39.
  16. Mellemkjaer L., Blot W., Sorensen H. et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br. J. Clin. Pharmacol. 2002; 53: 173-181.
  17. Fries J. Non-steroidal anti-inflammatory drug safety: a view from the ARAMIS databank. Curr. Opt. Rheum. 1996; 9: 3-7.
  18. Steen S., Lems W., Aertsen J. et al. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2001; 60: 443-447.
  19. Van Staa Т., Abenhaim L., Leufkens H. Selective prescribing of non steroidal anti-inflammatory drugs - implications for post-marketing surveillance. Post-market. Surveillance 1992; 5: 339-349.
  20. Abenhaim L., Moride Y. The effect of baseline susceptibility on the relative gastrotoxicity on individual NSAID in the elderly: a study with Quebec database. Post-market. Surveillance 1993; 7: 176.
  21. Weil J., Langman M., Wainwright P. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27-31.
  22. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000; 343: 1520-1528.
  23. Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
  24. Hawkey C., Wilson I., Naesdal J. et al. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesion in non-steroidal anti-inflammatory drug users. Gut 2002; 51: 344-350.
  25. Yeomans N., Lanas A., Talley N. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 2005; 22: 95-101.
  26. Ekstrom P., Carling L., Wetterhus S. et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand. J. Gastroenterol. 1996; 31: 753-758.
  27. Hawkey C., Karrasch J., Szczepanski L. et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 1998; 338: 727-734.
  28. Yeomans N., Tulassay Z., Juhasz L. et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 1998; 338: 719-726.
  29. Graham D. et al. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs. Arch. Intern. Med. 2002; 162: 1.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies